Tesamorelin, a synthetic peptide analogue of growth hormone-releasing hormone (GHRH), has been widely studied for its potential therapeutic applications, particularly in the context of HIV-associated lipodystrophy (HALS). It consists of 44 amino acids and functions by stimulating the pituitary gland to produce and secrete growth hormone (GH).
According to research, Tesamorelin can significantly reduce visceral adipose tissue (VAT) leading to improved lipid profiles and insulin sensitivity, suggesting potential benefits for cardiovascular health.
Tesamorelin has also been shown to increase IGF-1 (Insulin-like Growth Factor 1) levels, which Switzerland research suggests is beneficial for muscle growth, recovery, and overall metabolic function.
Showing all 5 results
[1] https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC6766405/
[2] https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC4601733/
[3] https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC8243807/
[4] https://pubmed.ncbi.nlm.nih.gov/ 21668043/
[5] https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC5633509/
[6] https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC3673013/
[7] https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC3513535/
[8] https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC3038486/
ALL CONTENT AND PRODUCT INFORMATION AVAILABLE ON THIS WEBSITE IS FOR EDUCATIONAL PURPOSES ONLY.
DISCLAIMER: These products are intended solely as a research chemical only. This classification allows for their use only for research development and laboratory studies. The information available on our Direct Peptides website: https://switzerland.direct-peptides.com is provided for educational purposes only. These products are not for human or animal use or consumption in any manner. Handling of these products should be limited to suitably qualified professionals. They are not to be classified as a drug, food, cosmetic, or medicinal product and must not be mislabelled or used as such.
401 N. Mills Ave, Ste B, Orlando, FL 32803, United States